Securities code: Zjamp Group Co.Ltd(002758) securities abbreviation: Zjamp Group Co.Ltd(002758) Announcement No.: 2022025
Bond Code: 128040 bond abbreviation: Huatong convertible bond
On establishing a special account for raised funds and authorizing the signing
Announcement of tripartite supervision agreement for raised funds
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Zjamp Group Co.Ltd(002758) (hereinafter referred to as "the company") deliberated and approved the proposal on establishing a special account for raised funds and authorizing the signing of a third-party supervision agreement at the 20th meeting of the 4th board of directors and the 17th meeting of the 4th board of supervisors held on February 28, 2022, and agreed that the company should establish a raised funds account for the storage and use of the raised funds of the changed project. In accordance with relevant laws such as the CSRC's guidelines for the supervision of listed companies No. 2 - regulatory requirements for the management and use of raised funds by listed companies, the stock listing rules of Shenzhen Stock Exchange, the guidelines for the self-discipline supervision of listed companies of Shenzhen Stock Exchange No. 1 - standardized operation of listed companies on the main board According to the relevant provisions of laws and regulations, normative documents and the company's measures for the administration of raised funds, this matter is within the approval authority of the board of directors and does not need to be submitted to the general meeting of shareholders for deliberation.
1、 Basic information of funds raised by the company's initial public offering
Approved by the reply on Approving the initial public offering of shares of Zhejiang Huatong Pharmaceutical Co., Ltd. (zjxk [2015] No. 838) issued by China Securities Regulatory Commission and approved by Shenzhen Stock Exchange, the company issued 14 million RMB common shares (A shares) for the first time at an issue price of 18.04 yuan per share, The total amount of funds raised in this offering is 252.56 million yuan. After deducting the expenses related to the offering of 315832 million yuan, the net amount of funds raised is 2209768 million yuan. All the above funds were paid in on May 22, 2015, which was verified by Lixin Certified Public Accountants (special general partnership) and issued the capital verification report (xksbz [2015] No. 610388). The funds raised by the company are used for the three projects of "pharmaceutical logistics phase II construction project", "chain drugstore expansion project" and "pharmaceutical wholesale business expansion project", and the raised funds are stored in a special account.
The investment projects and use plans of the funds raised from the initial public offering disclosed in the prospectus of the company's initial public offering are as follows:
Unit: 10000 yuan
No. total investment amount of raised funds project investment amount of raised funds to be used
1 pharmaceutical logistics phase II construction project 12024521202452
2 chain drugstore expansion project 690247607316
3 pharmaceutical wholesale business expansion project 673209400000
Total 25659082209768
2、 Changes of investment projects with raised funds
The first extraordinary general meeting of shareholders of the company in 2022 held on January 10, 2022 deliberated and approved the proposal on closing part of the company's raised investment projects, permanently supplementing the surplus raised funds with working capital and changing the purpose of part of the raised funds. In view of the fact that the "pharmaceutical logistics phase II construction project" and "pharmaceutical wholesale business expansion project" of the raised investment project have reached the predetermined usable state, and the raised funds are no longer planned to be used for the project in the future, the company will permanently supplement the working capital with the surplus raised funds after the completion of the "pharmaceutical logistics phase II construction project" and "pharmaceutical wholesale business expansion project", Used for daily business activities related to the company's main business. At the same time, the company changed the purpose of the remaining raised funds of the "chain drugstore expansion project" to "digital system upgrading and construction project" in combination with the actual operation, and the implementation subject is Zjamp Group Co.Ltd(002758) and its wholly-owned subsidiary Zhejiang Agricultural Materials Group Co., Ltd.
3、 Establishment of special account for raised funds
In order to standardize the management and use of raised funds and safeguard the legitimate rights and interests of investors. Zhejiang Agricultural Materials Group Co., Ltd. plans to open a special fund-raising account in China Citic Bank Corporation Limited(601998) Hangzhou Xihu sub branch for the fund storage and use of the "digital system upgrading and construction project". At the same time, the board of directors of the company authorizes the management and relevant functional departments of the company to open an account and sign a tripartite supervision agreement on raised funds and other relevant matters with the sponsor and the deposit bank of raised funds. After signing the supervision agreement on raised funds, the company will timely perform the corresponding information disclosure obligations.
4、 Documents for future reference
1. Resolutions of the 20th meeting of the 4th board of directors of the company;
2. Resolution of the 17th meeting of the 4th board of supervisors of the company.
It is hereby announced.
Zjamp Group Co.Ltd(002758) board of directors March 1, 2022
